Top

Published in:

Open Access 01-11-2012 | Original article

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

Authors: Erik H. J. G. Aarntzen, I. Jolanda M. de Vries, Joop H. Göertz, Marjo Beldhuis-Valkis, Huberdina M. L. M. Brouwers, Mandy W. M. M. van de Rakt, Renate G. van der Molen, Cornelis J. A. Punt, Gosse J. Adema, Paul J. Tacken, Irma Joosten, Joannes F. M. Jacobs

Published in: Cancer Immunology, Immunotherapy | Issue 11/2012

Abstract

Purpose

Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it has not been possible to monitor the dynamics of KLH-specific antibody (Ab) responses after in vivo KLH exposure. We designed a quantitative assay to measure KLH-specific Abs in humans and retrospectively studied the relation between vaccination parameters and the vaccine-induced anti-KLH Ab responses.

Experimental design

Anti-KLH Abs were purified from pooled serum of melanoma patients who have responded to KLH as a vaccine adjuvant. Standard isotype-specific calibration curves were generated to measure KLH-specific Ab responses in individual serum samples using ELISA.

Results

KLH-specific IgM, IgA, IgG and all IgG-subclasses were accurately measured at concentrations as low as 20 μg/ml. The intra- and inter-assay coefficients of variation of this ELISA were below 6.7 and 9.9 %, respectively. Analyses of 128 patients demonstrated that mature DC induced higher levels of KLH-specific IgG compared to immature DC, prior infusion with anti-CD25 abolished IgG and IgM production and patients with locoregional disease developed more robust IgG responses than advanced metastatic melanoma patients.

Conclusions

We present the first quantitative assay to measure KLH-specific Abs in human serum, which now enables monitoring both the dynamics and absolute concentrations of humoral immune responses in individuals exposed to KLH. This assay may provide a valuable biomarker for the immunogenicity and clinical effectiveness of KLH-containing vaccines and therapies.

Available only for authorised users

Harris JR, Markl J (1999) Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30(6):597–623PubMedCrossRef

Swanson MA, Schwartz RS (1967) Immunosuppressive therapy. The relation between clinical response and immunologic competence. N Engl J Med 277(4):163–170PubMedCrossRef

Perabo FG, Muller SC (2004) Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64(3):409–421PubMedCrossRef

Schumacher K (2001) Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders. J Cancer Res Clin Oncol 127(Suppl 2):R1–R2PubMedCrossRef

Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO (2012) Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother 61(1):9–18PubMedCrossRef

Gandhi RT, O’Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM (2009) A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells versus canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27(43):6088–6094PubMedCrossRef

Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372–383PubMedCrossRef

Leonhartsberger N, Ramoner R, Putz T, Gander H, Rahm A, Falkensammer C, Bartsch G, Thurnher M (2007) Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol Immunother 56(6):897–903PubMedCrossRef

Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U (2003) Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 104(2):188–194PubMedCrossRef

10.

Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C (2009) Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32(5):498–507PubMedCrossRef

11.

Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, Blokx W, Vankrieken JH, Joosten I, Boerman OC, Oyen WJ, Adema G, Punt CJ, Figdor CG, De Vries IJ (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15(7):2531–2540PubMedCrossRef

12.

Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475–480PubMedCrossRef

13.

De Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9(14):5091–5100PubMed

14.

Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, De Vries IJ, Adema GJ (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Clin Cancer Res 16(20):5067–5078PubMedCrossRef

15.

Lesterhuis WJ, De Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17(17):5725–5735PubMedCrossRef

16.

De Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23(11):1407–1413PubMedCrossRef

17.

Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58(1):1–14PubMedCrossRef

18.

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006) Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13(10):905–918PubMedCrossRef

19.

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2007) T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 56(5):659–675PubMedCrossRef

20.

Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethe B, De Plaen E, Velu T, Boon T, Coulie PG (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201(2):241–248PubMedCrossRef

21.

De Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23(24):5779–5787PubMedCrossRef

22.

Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, Mendoza-Naranjo A, Larrondo M, Compan A, Ferrada C, Salazar-Onfray F (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27(6):945–952PubMedCrossRef

23.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 60(1):15–22PubMedCrossRef

24.

Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57(3):303–315PubMedCrossRef

25.

Neelapu SS, Baskar S, Kwak LW (2001) Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol 127(Suppl 2):R14–R19PubMedCrossRef

26.

Spazierer D, Skvara H, Dawid M, Fallahi N, Gruber K, Rose K, Lloyd P, Heuerding S, Stingl G, Jung T (2009) T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. Clin Exp Allergy 39(7):999–1008PubMedCrossRef

27.

Kelly BS, Levy JG, Sikora L (1979) The use of the enzyme-linked immunosorbent assay (ELISA) for the detection and quantification of specific antibody from cell cultures. Immunology 37(1):45–52PubMed

28.

Korver K, Zeijlemaker WP, Schellekens PT, Vossen JM (1984) Measurement of primary in vivo IgM- and IgG-antibody response to KLH in humans: implications of pre-immune IgM binding in antigen-specific ELISA. J Immunol Methods 74(2):241–251PubMedCrossRef

29.

Oyelaran O, Gildersleeve JC (2010) Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteom Clin Appl 4(3):285–294CrossRef

30.

Lesterhuis WJ, De Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ (2006) Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 17(6):974–980PubMedCrossRef

31.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, De Vries IJ, Punt CJ (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60(2):249–260PubMedCrossRef

32.

Lane HC, Volkman DJ, Whalen G, Fauci AS (1981) In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements. J Exp Med 154(4):1043–1057PubMedCrossRef

33.

Stavnezer J (1996) Immunoglobulin class switching. Curr Opin Immunol 8(2):199–205PubMedCrossRef

34.

Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27(1):1–18PubMedCrossRef

35.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131–145PubMedCrossRef

36.

Whiteside TL (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10(7):1019–1035PubMedCrossRef

37.

Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147–1154PubMedCrossRef

38.

Golub SH, Rangel DM, Morton DL (1977) In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer 20(6):873–880PubMedCrossRef

39.

Grant RW, Mariani RA, Vieira VJ, Fleshner M, Smith TP, Keylock KT, Lowder TW, McAuley E, Hu L, Chapman-Novakofski K, Woods JA (2008) Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults. Brain Behav Immun 22(6):923–932PubMedCrossRef

40.

Jurincic-Winkler CD, von der Kammer H, Beuth J, Scheit KH, Klippel KF (1996) Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Anticancer Res 16(4A):2105–2110PubMed

Title: Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters
Authors: Erik H. J. G. Aarntzen
I. Jolanda M. de Vries
Joop H. Göertz
Marjo Beldhuis-Valkis
Huberdina M. L. M. Brouwers
Mandy W. M. M. van de Rakt
Renate G. van der Molen
Cornelis J. A. Punt
Gosse J. Adema
Paul J. Tacken
Irma Joosten
Joannes F. M. Jacobs
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1263-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation

Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease

Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer